Study to Assess Pulsed, Inhaled Nitric Oxide (iNO) in Subjects at Risk of Pulmonary Hypertension Associated with Pulmonary Fibrosis on Long Term Oxygen Therapy (Part 1 and Part 2)
Recruiting
18 years - 80 years
All
5 participants needed
1 Location
Brief description of study
The purpose of this study is to determine if the INOpulse® delivery system, that includes the INOpulse® device, inhaled nitric oxide study drug as delivered via triple lumen nasal cannula can help treat patients with fibrotic interstitial lung disease (fILD) who are on oxygen therapy and who are at risk of having or developing pulmonary hypertension associated with pulmonary fibrosis (PH-PF). Specifically, the study will determine if the use of the INOpulse® delivery system can help improve daily levels of moderate to vigorous types of physical activity (for example walking, climbing stairs, household chores and cleaning and, exercise and hobbies), as measured by an activity monitor (a non-invasive way to monitor rest/activity).
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: interstitial lung disease,ILD,Pulmonary Hypertension,Pulmonary Fibrosis
-
Age: 18 years - 80 years
-
Gender: All
Updated on
04 Aug 2024.
Study ID: 850447